Application of recombinant TAF3 PHD domain instead of anti-H3K4me3 antibody by Kungulovski, G. et al.
Kungulovski et al. Epigenetics & Chromatin  (2016) 9:11 
DOI 10.1186/s13072-016-0061-9
Application of recombinant TAF3 PHD domain 
instead of anti-H3K4me3 antibody
Kungulovski et al. 
Epigenetics & Chromatin
Kungulovski et al. Epigenetics & Chromatin  (2016) 9:11 
DOI 10.1186/s13072-016-0061-9
METHODOLOGY
Application of recombinant TAF3 PHD 
domain instead of anti-H3K4me3 antibody
Goran Kungulovski1†, Rebekka Mauser1†, Richard Reinhardt2 and Albert Jeltsch1* 
Abstract 
Background: Histone posttranslational modifications (PTMs) represent a focal point of chromatin regulation. The 
genome-wide and locus-specific distribution and the presence of distinct histone PTMs is most commonly examined 
with the application of histone PTM-specific antibodies. In spite of their central role in chromatin research, polyclonal 
antibodies suffer from disadvantages like batch-to-batch variability and insufficient documentation of their quality 
and specificity.
Results: To mitigate some of the pitfalls of using polyclonal antibodies against H3K4me3, we successfully validated 
the application of a recombinant TAF3 PHD domain as anti-H3K4me3 affinity reagent in peptide array, western blot 
and ChIP-like experiments coupled with qPCR and deep sequencing.
Conclusions: The successful addition of the TAF3 PHD domain to the growing catalog of recombinant affinity 
reagents for histone PTMs could help to improve the reproducibility, interpretation and cross-laboratory validation of 
chromatin data.
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Background
The N-terminal tails of histones stick out from the core 
nucleosome and are subject to more than a 100 of post-
translational modifications (PTMs) [1, 2]. Many of these 
histone PTMs lie in the focal point of chromatin regula-
tion and contribute to numerous cellular processes such 
as development and disease [3–5]. Due to their central 
role in essential cellular processes, their systematic map-
ping has been a prime concern of many scientific consor-
tia such as ENCODE, Roadmap Epigenomics, Blueprint 
Epigenome and IHEC. The genome-wide and locus-spe-
cific density and distribution of distinct histone PTMs is 
typically examined with the help of histone PTM-specific 
antibodies, which are used to precipitate modified chro-
matin, followed by further downstream analyses. Because 
of this, the antibody is the principal mediator relaying the 
information about the presence and distribution of an 
individual histone modification, and its properties should 
be of highest quality and well documented [6]. However, 
there are several constitutional difficulties of recogniz-
ing histone PTM epitopes by antibodies, because of their 
small size, the chemical similarity of numerous histone 
PTMs, the hypermodified nature of histone tails where 
one modification can influence the detection of another, 
and the similarities in the amino acid motifs surround-
ing the modified residues. Hence, critical properties of 
antibodies include various features such as their speci-
ficity with respect to the tested modification and its 
amino acid sequence context, their cross-reactivity and 
their response to the presence of secondary modifica-
tions. This inherent complexity is further exacerbated by 
the large variability of these critical properties between 
antibody lots (in case of polyclonal antibodies). Moreo-
ver, even broadly used antibodies occasionally lack the 
expected specificity, and the quality of datasheets pro-
vided by companies is insufficient in general [6–12].
To mitigate some of the above-mentioned draw-
backs related to histone PTM antibodies, recently we 
have devised a strategy of using recombinant histone 
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modification interacting domains (HiMIDs) instead of 
antibodies in different experimental settings such as 
western blot and chromatin precipitation coupled with 
deep sequencing [9]. This approach is complementary 
to alternative strategies of using recombinant antibodies 
in ChIP experiments [13] as well as using recombinant 
HiMIDs in chromatin precipitation studies coupled with 
mass spectrometry [14]. The cheap production of recom-
binant HiMIDs in Escherichia coli, their amenability to 
protein engineering and the unlimited availability of 
recombinant proteins with constant properties have the 
potential to solve many of the contemporary problems 
in chromatin biology such as lab-to-lab and long-term 
reproducibility of results, and insufficient documentation 
of the intricate critical properties of affinity reagents [6, 
11].
So far we have validated recombinant HiMIDs against 
histone PTMs such as H3K9me3, H3K9me3/K4unmodi-
fied, H3K27me3 and H3K36me3 [9]. However, no HiMID 
was available to study the lysine 4 trimethylation of his-
tone H3 (H3K4me3), which is one of the most impor-
tant and widely studied histone marks, highly conserved 
from yeast to mammals [15, 16]. It is considered a land-
mark of promoters, especially promoters of active genes 
[17]. The TATA box-binding protein-associated fac-
tor 3 (TAF3) protein is involved in anchoring the TFIID 
basal transcription factor to nucleosomes containing 
H3K4me3 through its PHD domain, thereby stimulat-
ing pre-initiation complex formation [18, 19]. Moreover, 
the interaction of TAF3 PHD and H3K4me3 is involved 
in p53-dependent regulation of genes upon genotoxic 
insults [19]. In this study, we systematically examined the 
applicative potential of the TAF3 PHD domain [18, 20] 
in chromatin biology as a substitute of anti-H3K4me3 
antibodies. Herein, we demonstrate that the TAF3 PHD 
domain performs similarly to ENCODE-validated anti-
bodies in western blot and ChIP-seq-like experiments 
highlighting its applicative potential to replace anti-
H3K4me3 antibodies.
Results
Previous studies have demonstrated that the recom-
binant TAF3 PHD domain can be used to precipitate 
H3K4me3-enriched chromatin [18]. In order to inves-
tigate the applicative capabilities of the recombinant 
GST-tagged TAF3 PHD domain as an H3K4me3 affinity 
reagent, we closely followed the quality control guide-
lines set by the ENCODE consortium [7, 21] and recently 
upgraded by us [6]. The set of guidelines dictates that 
the tested affinity reagent (antibody or reading domain) 
should perform successfully in at least three out of four 
key experiments: (1) specific binding to peptide arrays 
or another high-throughput peptide-based platform; (2) 
binding to native histones and lack of binding to recom-
binant histones in western blot experiments; (3) loss of 
signal in western blot experiments with native histones, 
where the targeted histone PTM has been depleted; and 
(4) successful precipitation of chromatin, reproducibil-
ity of ChIP-seq data and high correlation with validated 
ChIP-seq datasets.
Peptide array and western blot analyses of TAF3 PHD 
and anti‑H3K4me3 antibody
First, we probed the TAF3 PHD domain on CelluS-
pots peptide arrays, which have been used in previous 
reports to study the specificity of histone PTM read-
ing domains [22–25]. The TAF3 PHD domain exhibited 
binding to H3K4me3-modified peptides. Focusing on 
the effects of adjacent marks, we observed inhibition of 
binding in the presence of H3R2me2 (as reported before 
[18, 20]), H3T3ph (as reported before [26]) and H3R2citr 
(Fig.  1a). We did not observe a trimethyllysine-specific 
binding at any other lysine residues (data not shown). 
The H3K4me3-specific interaction was confirmed with 
a TAF3 PHD M882A mutant that has been reported to 
have a diminished binding affinity to H3K4me3 peptides 
[18, 20]. The recombinant TAF3 PHD M882A mutant 
was generated and purified with similar yield and purity 
as the TAF3 PHD WT (Additional file  1: Fig. S1A) but 
did not show interaction on peptide arrays (Additional 
file 1: Fig. S1B).
To additionally confirm the PTM-dependent interac-
tion and also check for possible cross-reactivity with 
modified non-histone proteins, we carried out far-west-
ern blot experiments with nuclear extracts containing 
native histones and recombinant histones H3 and H4, 
where the TAF3 PHD reading domain was used instead 
of an anti-H3K4me3 antibody. The domain bound spe-
cifically to native histones, but not recombinant histones, 
which do not carry any PTMs (Fig. 1b). The dependence 
of the interaction on an intact H3K4me3 binding pocket 
was again validated with a TAF3 PHD M882A pocket 
mutant (Additional file 1: Fig. S1C). To further verify that 
the interaction was dependent on the presence of the 
H3K4 methylation mark, we isolated histones from Sac-
charomyces cerevisiae wild-type (WT) and Set1 knockout 
cells (ΔSet1) and carried out western blot experiments. 
Set1 is the only H3K4 methyltransferase in S. cerevisiae, 
so that histones isolated from Set1 knockout cells are free 
of H3K4me3. In agreement with the previous data, the 
TAF3 PHD domain showed specific binding to histones 
isolated from WT cells, but not to histones isolated from 
Set1 KO cells (Fig. 1c), again confirming the specificity of 
interaction.
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Chromatin precipitation coupled with deep sequencing 
of TAF3 PHD and anti‑H3K4me3 antibody
Chromatin immunoprecipitation (ChIP) is by far the 
most prevalent method for studying the genomic pres-
ence and distribution of histone PTMs. For this aim, we 
sought to evaluate the performance of the TAF3 PHD 
domain in ChIP-like experiments, which we call chro-
matin interacting domain precipitation (CIDOP). The 
chromatin used for our studies consisted primarily of 
mononucleosomes (Additional file  1: Fig. S2C) iso-
lated from HepG2 cells, and ChIP experiments with a 
widely used anti-H3K4me3 antibody were performed 
in parallel with the CIDOP experiments. First, we vali-
dated the specificity of the precipitation with quantita-
tive PCR of amplicons covering promoter-proximal and 
promoter-distal regions of the VEGF-A and PABPC1 
genes, and additional H3K36me3- and H3K9me3-
enriched regions (Fig. 2a, b; Additional file 1: Fig. S2A, 
B). Both, the TAF3 PHD domain and the anti-H3K4me3 
antibody, performed similarly by specifically enrich-
ing for nucleosomes in promoter-proximal regions and 
showing residual binding for promoter-distal and con-
trol regions. The specificity was further validated with 
the TAF3 PHD M882A pocket mutant, where only 
non-specific residual binding was observed (Additional 
file 1: Fig. S3).
Our next objective was to extend the CIDOP-qPCR 
experiments to a genome-wide level. We carried out 
CIDOP-seq experiments, where our data were com-
pared head to head with two ChIP-seq datasets obtained 
with anti-H3K4me3 antibodies in HepG2 cells avail-
able from ENCODE. Our CIDOP-seq data showed high 
concordance with both ChIP-seq datasets at the VEGF-A 
locus, but some differences were observed with the anti-
body dataset 1 (but not dataset 2) at the PABPC1 locus 
(Fig.  2c), again highlighting the possible discrepancies 
emerging from using two different antibodies against 
the same histone PTM in the ENCODE data. Neverthe-
less, detailed genome-wide analyses demonstrated a high 
concordance between our CIDOP-seq data and both 
ENCODE ChIP-seq datasets (Fig. 3; Additional file 1: Fig. 
S5A).
Genomic distribution of TAF3 CIDOP‑seq signal
We next tested the genome-wide distribution of the 
TAF3 CIDOP signal and its enrichment in particular 
genomic elements and compared the results with corre-
sponding analyses of the H3K4me3 ChIP data. First, the 
TAF3 PHD CIDOP-seq and anti-H3K4me3 ChIP-seq 
datasets showed high genome-wide correlation of raw 
read densities with each other but not with H3K9me3 
signal obtained with the MPP8 chromo domain used 
as an outgroup here (Fig.  3a). The H3K4me3 modifica-
tion has been reported to be enriched in promoters and 
CpG islands [17, 27] where we observed a similarly high 
correlation of signals (Fig.  3a). Peak calling was carried 
out for all datasets, and the highest number of peaks 
was detected in antibody experiment 1. We performed 
k-means clustering of our CIDOP-seq together with the 
ENCODE H3K4me3 ChIP-seq raw read densities cen-
tered around the peaks identified in antibody experi-
ment 1 (Fig. 3b). We observed clear signal at all peaks in 
all experiments illustrating the high concordance of all 
datasets. However, the signal intensity differed at some 
Fig. 1 Specificity analyses of TAF3 PHD and anti-H3K4me3 antibody. a Peptide array profiling of TAF3 PHD. b Western blot analyses with TAF3 PHD 
and anti-H3K4me3 antibody with native histones carrying H3K4me3 (NH) and recombinant histones (RH) which are free of histone PTMs. c Western 
blot analyses with TAF3 PHD and anti-H3K4me3 antibody with lysates isolated from S. cerevisiae wild-type (WT) or Set1 knockout (ΔSet1) cells, which 
do not contain H3K4me3
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clusters, which caused variances in the number of called 
peaks in individual experiments. Nevertheless, the dis-
tributions of peaks obtained with both methods showed 
high overlap with each other, and between their respec-
tive replicates as well (Additional file  1: Fig. S4). Most 
importantly, the technical variances in peak distribu-
tions between experiments and repeats were of similar 
magnitude as the variances between CIDOP and ChIP. 
Next, we examined and compared the distribution of 
CIDOP-seq and ChIP-seq signals in a metagene analysis 
of all human genes and observed very similar signal dis-
tributions, peaking around the TSS and decreasing inside 
the gene body (Fig. 3c). Moreover, both datasets showed 
almost identical peak distributions in genomic elements, 
with high enrichment in promoters as expected (Fig. 3d). 
Next, we performed k-means clustering of our CIDOP-
seq together with the ENCODE H3K4me3 and RNA 
pol II ChIP-seq datasets centered on CpG islands and 
Fig. 2 CIDOP and ChIP carried out with TAF3 PHD and anti-H3K4me3 antibody. a CIDOP-qPCR signals using amplicons covering the VEGF-A, PABPC1 
loci and control regions. For details about the positions of the VEGF-A and PABPC1 amplicons, refer to (Additional file 1: Fig. S2A, B). b ChIP-qPCR 
signals using the same amplicons as a. c Representative genome browser views comparing CIDOP-seq and ChIP-seq (from ENCODE) signals taken 
from both experiments/replicates for each method, respectively. Zoom in at the VEGF-A locus (upper panel) and PABPC1 locus (lower panel). Note the 
difference in the PABPC1 locus between anti-H3K4me3 experiment 1 and all three other datasets. For additional browser views, refer to Additional 
file 1: Fig. S5A
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promoters. We observed enrichment of H3K4me3 signal 
(detected by domain and antibodies) in RNA pol II rich 
clusters, again confirming the legitimate distribution of 
our data (Additional file 1: Fig. S5B, C).
Since the H3K4me3 mark is typically found within 
open chromatin and unmethylated CpG islands [28, 
29], we examined its overlap with DNase I-hypersen-
sitive sites and RRBS data of unmethylated CpGs, from 
Fig. 3 CIDOP-seq and ChIP-seq carried out with TAF3 PHD and anti-H3K4me3 antibody. a Spearman’s correlation coefficient in 1-kb bins genome-
wide (upper heatmap) or Pearson’s correlation coefficient between CIDOP-seq and ChIP-seq signals within promoters (middle heatmap) and within 
CpG islands (lower heatmap). b Clustering analysis of tag densities from TAF3 PHD and anti-H3K4me3 datasets. Tags were collected in 6-kb windows, 
centered on the midpoints of anti-H3K4me3 exp1 peaks (which was the experiment with the highest number of detected peaks) and sorted by 
k-means clustering (ten clusters). c Composite profiles of TAF3 PHD and anti-H3K4me3 antibody distribution over metagenes fitted in 5-kb gene 
bodies and 1-kb flanks from the TSS/TTS. d Distribution of CIDOP-seq and ChIP-seq peaks among different genomic elements
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ENCODE. Peaks obtained from TAF3 PHD CIDOP-seq 
and anti-H3K4me3 ChIP-seq showed similar overlap 
with open chromatin and unmethylated CpGs (Fig. 4a, b). 
Lastly, we explored the distribution of peaks from both 
datasets in different chromatin segments and repeats as 
defined by Ernst et  al. [30]. The enrichment in actively 
transcribed chromatin segments and depletion in repeat 
elements further demonstrated the similarity between 
the CIDOP-seq and ChIP-seq datasets and their proper 
genomic enrichment and distribution (Fig. 4c; Additional 
file 1: Fig. S6).
Discussion
Antibodies have been “the jack of all trades” in biol-
ogy in the past century and remain in the focal point of 
experimental chromatin biology, especially in translat-
ing the complex syntax of the language of histone marks 
into properties that can be experimentally analyzed. 
H3K4me3 is one of the best characterized histone PTMs, 
although its direct and multifaceted functional role in 
transcription is still not fully understood [15, 16, 31]. The 
importance of this histone mark in basic chromatin biol-
ogy makes the development of novel H3K4me3-specific 
affinity tools and the refinement of old ones a principal 
goal in molecular biotechnology. We screened several 
potential H3K4me3 readers such as BPTF-PHD [32], 
RAG2-PHD [33] and found TAF3-PHD [18] the most 
promising in our hands. Another study recently showed 
that the ING2-PHD might work for this type of applica-
tions as well [14].
In this work, we demonstrated that the recombinant 
TAF3 PHD domain can be used as a specific, reliable and 
reproducible alternative to anti-H3K4me3 antibodies. 
With rigorous characterization of its experimental per-
formance, following established guidelines and criteria 
[6, 7, 11, 21], we have included another member to the 
growing catalog of recombinant affinity reagents for his-
tone PTMs [9, 13]. These reagents are characterized by 
a consistent performance and the absence of lot-to-lot 
variability due to recombinant production. The poten-
tial problems caused by lot-to-lot variance in antibody 
properties are illustrated in our data, where the two 
H3K4me3 datasets available from ENCODE showed a 
larger variation than the two repeats of our TAF3 PHD-
based CIDOP experiments. While other reasons can-
not be excluded, one critical parameter in the ENCODE 
H3K4me3 ChIP data is the application of two different 
antibodies. Unfortunately, this question cannot be fully 
resolved, because the corresponding antibody batches 
are no longer available, so that no retrospective specific-
ity analyses of the antibodies and ChIP-seq can be con-
ducted. In contrast, due to their recombinant production, 
Fig. 4 CIDOP-seq and ChIP-seq carried out with TAF3 PHD and anti-H3K4me3 antibody. a Percent of at least 10 % overlap of TAF3 PHD and anti-
H3K4me3 peaks (merged from both replicates or experiments, respectively) and randomized shuffled genomic coordinates of the same number, 
with DNase I-sensitive sites. b Same analysis carried out with unmethylated DNA from RRBS data. c Overlap of H3K4me3 signals with different 
chromatin segments defined by Ernst et al. [30]. Please note the enrichment in segments associated with actively transcribed chromatin
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the availability of recombinant reading domains is unlim-
ited and future batches will show identical properties 
(if the purification procedures are not altered), allow-
ing for unlimited follow-up studies and experimental 
reproductions.
Conclusions
Trimethylation of histone H3 at K4 is an important his-
tone PTM associated with active promoters. The work 
presented here, including western blot, CIDOP-qPCR 
and CIDOP-seq, clearly illustrates that the TAF3 PHD 
domain can be applied as a reliable substitute of anti-
H3K4me3 antibodies. The continuous growth of the 
catalog of recombinant reagents with constant and well-
documented properties should foster the replacement of 
polyclonal antibodies by HiMIDs in routine applications. 
This could help to improve the reproducibility, interpre-
tation and cross-laboratory validation of chromatin data.
Methods
Cloning, site‑directed mutagenesis, expression 
and purification
The sequence encoding the PHD domain from TAF3 
(amino acids 856–929 of NCBI Reference Sequence 
NP_114129.1.1) was amplified from cDNA and cloned 
as a GST fusion protein into pGEX-6p-2 vector (GE 
Healthcare). It was overexpressed at 20 °C in the presence 
of 50  µM zinc in LB medium, induced 1  mM IPTG at 
0.6–0.8 OD600 and purified by affinity chromatography as 
described [34]. The M882A mutation was introduced by 
site-directed mutagenesis [35] and validated by restric-
tion analysis and Sanger sequencing.
Peptide arrays and western blot analyses
For western blot, native histones were isolated by acid 
extraction [36] from HEK293 cells and recombinant his-
tones H3 and H4 were purchased from New England 
Biolabs. Two and a half micrograms of native histones 
and one microgram of recombinant histone H3 and H4 
each were electrophoresed on a 16–18 % SDS-PA gel and 
transferred on a nitrocellulose membrane. Lysates from 
S. cerevisiae were isolated by bead beating, precipitated 
with 0.2 M H2SO4 and boiled in LAP. From now on, the 
CelluSpots peptide arrays (Active Motif, Carlsbad, CA, 
USA) and nitrocellulose membranes were treated the 
same.
The CelluSpots peptide arrays or nitrocellulose mem-
branes were blocked by incubation in TTBS (10  mM 
Tris/HCl pH 7.5, 0.05  % Tween-20 and 150  mM NaCl) 
containing 5  % skim milk at +4  °C overnight, then 
washed two times with TTBS and one time with interac-
tion buffer (300 mM KCl, 20 mM HEPES pH 7.5, 0.1 mM 
DTT and 10  % glycerol) and incubated with 10  nM of 
recombinant TAF3 PHD in interaction buffer for 2  h. 
Afterward, the arrays or membranes were washed two 
times with interaction buffer (with 300–500  mM KCl) 
and once with TTBS and incubated with primary anti-
GST antibody for 1  h. After three washes with TTBS, 
the arrays or membranes were incubated with secondary 
anti-goat antibody for 1 h. Details regarding the protocol 
and the bioinformatic analysis are described in [37]. The 
antibodies were incubated with the membranes following 
the manufacturer’s recommendations for western blot.
Chromatin precipitation and deep sequencing analysis
Native nucleosomes were isolated from HepG2 cells 
by micrococcal digestion of intact nuclei obtained as 
described [38]. Upon isolation of nuclei and micrococ-
cal nuclease digestion, the protocol was modified in the 
following way: The MNase digestion was stopped with 
2 mM EGTA and afterward the sample was sonicated for 
five cycles (20 s pulse, 30 s pause) with EpiShear Sonica-
tor (Active Motif, Carlsbad, CA, USA). After sonication, 
the sample was centrifuged at 13,000×g for 10 min, and 
the resulting supernatant was taken as a nucleosomal 
fraction (predominantly nucleosomes). Then, native 
chromatin (30–60  µg, based on DNA absorbance) was 
incubated with 30–60 µg of recombinant TAF3 PHD, or 
anti-H3K4me3 antibody (ab8580, lot: GR85670-1), used 
following the manufacturer’s recommendations) in DP 
buffer (16.7  mM Tris–Cl, 167  mM NaCl, 1.1  % Triton 
X-100 and protease inhibitors) overnight with rotation. 
The domain–chromatin complexes were immobilized on 
20–40  µl glutathione Sepharose 4B beads (GE Health-
care), washed three times with PB300 buffer (50  mM 
Tris–Cl, 300 mM NaCl, 0.5 % Nonidet P-40, 2 mM DTT). 
Elution, DNA recovery and qPCR were done essentially 
as described [9]. The primer sequences used in this study 
are shown in Additional file 1: Table S1.
Before proceeding to Illumina sequencing on the 
HiSeq 2500 platform, the quality of DNA precipitation 
and library generation was checked with Bioanalyzer 
(Agilent Technologies, Santa Clara, CA, USA). Around 
10–15 million 100-nt sequence reads were obtained and 
mapped to hg38 with bowtie2, using the default set-
tings [39] within the Galaxy Platform [40], retaining only 
uniquely mapped reads. Peaks were called with MACS 
[41] in Galaxy using the default settings, except in the 
case of the TAF3 PHD replicate 2, where m-fold of 20 
instead of 32 was used. The peak annotation was done 
with CEAS within the Cistrome platform [42, 43], and 
the peak distribution and overlap with repeats and chro-
matin segments was determined with EpiExplorer [44]. 
The seqMINER tool was used for k-means clustering and 
heatmap generation [7], while the metagene profiles were 
generated in DeepTools [45].
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The Spearman correlation of raw data in 1-kb bins was 
done in DeepTools as well, but the Pearson correlation 
within CpG islands and promoters was carried out in 
SeqMonk (http://www.bioinformatics.babraham.ac.uk/
projects/seqmonk/) in window bins of 100 bp. Raw den-
sity profiles were generated in BEDTools [46], while 
RPKM normalized density profiles were generated in 
DeepTools [45] and visualized in the Integrative Genom-
ics Viewer [47]. The raw sequencing data for all ChIP-
seq (H3K4me3) experiments were downloaded from 
ENCODE, data from Broad Institute: (http://hgdown-
load.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEn-
codeBroadHistone/). The RNA pol II ChIP-seq data were 
downloaded from ENCODE, data from Myers lab: (wgEn-
codeHaibTfbsHepg2Pol2Pcr2xRawDataRep2.fastq.gz).
Data access
The CIDOP-seq raw data have been submitted to the 
ArrayExpress database (https://www.ebi.ac.uk/arrayex-
press/) under the accession number E-MTAB-4103. The 
raw input and H3K9me3 CIDOP-seq data were taken 
from [9] and can be found under the accession number 
E-MTAB-2143.
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